Darzalex Faspro
Non-small Cell Lung Cancer With STK11/LKB1 Mutation
NYU Langone HealthunclassifiedPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Non-small Cell Lung Cancer With STK11/LKB1 Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hyaluronidase fihj NYU Langone Health | Phase 2 | B |
Daratumumab-Hyaluronidase NYU Langone Health | Phase 2 | B |
Same molecule, other indications
Darzalex Faspro is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →